The Aspergillosis drugs in development market research report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Aspergillosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Aspergillosis and features dormant and discontinued products.

GlobalData tracks 40 drugs in development for Aspergillosis by 36 companies/universities/institutes. The top development phase for Aspergillosis is preclinical with 25 drugs in that stage. The Aspergillosis pipeline has 32 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Aspergillosis pipeline products market are: Pulmonomy, Lundquist Institute and Cellix Bio.

The key targets in the Aspergillosis pipeline products market include Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC, Ergosterol , and 1,3 Beta Glucan Synthase (EC

The key mechanisms of action in the Aspergillosis pipeline product include Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC Inhibitor with seven drugs in Pre-Registration. The Aspergillosis pipeline products include 11 routes of administration with the top ROA being Intravenous and eight key molecule types in the Aspergillosis pipeline products market including Small Molecule, and Monoclonal Antibody.

Aspergillosis overview

Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss, and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma, and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungals, and surgery.

For a complete picture of Aspergillosis’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.